Table 2 Use of pegfilgrastim prophylaxis in cycle 1, cycle 2, cycles 3+, last cycle, and all cycles, respectively, overall and by FN occurrence in a prior cycle*

  No

50,778 (100%)

16,512 (33%)

34,266 (67%)

–

71,037 (100%)

20,195 (28%)

50,842 (72%)

–

  Yes

–

–

–

–

–

–

–

–

Cycle 2

41,769

11,719 (28%)

30,050 (72%)

59,412

15,193 (26%)

44,219 (74%)

  No

40,123 (96%)

11,482 (29%)

28,641 (71%)

–

55,488 (93%)

14,483 (26%)

41,005 (74%)

–

  Yes

1646 (4%)

237 (14%)

1409 (86%)

2.4 (2.1–2.7)

3924 (7%)

710 (18%)

3214 (82%)

1.6 (1.5–1.7)

Cycles ≥3

98,075

24,834 (25%)

73,241 (75%)

141,495

43,012 (30%)

98,483 (70%)

  No

91,744 (94%)

23,875 (26%)

67,869 (74%)

–

126,424 (89%)

39,360 (31%)

87,064 (69%)

–

  Yes

6331 (6%)

959 (15%)

5372 (85%)

2.0 (1.8–2.1)

15,071 (11%)

3652 (24%)

11,419 (76%)

1.4 (1.4–1.5)

Last Cycle

34,860

10,188 (29%)

24,672 (71%)

51,989

20,099 (39%)

31,890 (61%)

  No

32,541 (93%)

9774 (30%)

22,767 (70%)

–

46,115 (89%)

18,215 (39%)

27,900 (61%)

–

  Yes

2319 (7%)

414 (18%)

1905 (82%)

2.0 (1.8–2.2)

5874 (11%)

1884 (32%)

3990 (68%)

1.4 (1.3–1.5)

All Cycles

190,622

53,065 (28%)

137,557 (72%)

271,944

78,400 (29%)

193,544 (71%)

  No

182,645 (96%)

51,869 (28%)

130,776 (72%)

–

252,949 (93%)

74,038 (29%)

178,911 (71%)

–

  Yes

7977 (4%)

1196 (15%)

6781 (85%)

2.2 (2.1–2.4)

18,995 (7%)

4362 (23%)

14,633 (77%)

1.4 (1.3–1.4)